Key information

🔎 Fund Overview

Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The Company has built FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical covalent programs for the treatment of select cancers.